Comparison 2. Effect of increasing behavioural support: Sensitivity analyses.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Sensitivity analysis including intermediate intensity conditions. Adjunct behavioural support versus pharmacotherapy alone	65	27425	Risk Ratio (M‐H, Random, 95% CI)	1.13 [1.07, 1.20]
1.1 NRT	49	18666	Risk Ratio (M‐H, Random, 95% CI)	1.10 [1.03, 1.19]
1.2 Bupropion	5	2298	Risk Ratio (M‐H, Random, 95% CI)	1.27 [1.10, 1.46]
1.3 Nortriptyline	2	172	Risk Ratio (M‐H, Random, 95% CI)	0.98 [0.60, 1.63]
1.4 Varenicline	2	1513	Risk Ratio (M‐H, Random, 95% CI)	1.06 [0.90, 1.26]
1.5 NRT & bupropion	3	719	Risk Ratio (M‐H, Random, 95% CI)	1.24 [1.00, 1.54]
1.6 Choice of pharmacotherapy	5	4057	Risk Ratio (M‐H, Random, 95% CI)	1.23 [1.00, 1.51]
2 By outcome definition	65	23389	Risk Ratio (M‐H, Random, 95% CI)	1.15 [1.08, 1.22]
2.1 12 months validation PP outcomes only	21	6036	Risk Ratio (M‐H, Random, 95% CI)	1.03 [0.90, 1.17]
2.2 12 months validated sustained outcomes	11	3604	Risk Ratio (M‐H, Random, 95% CI)	1.10 [0.93, 1.30]
2.3 < 12 months, but validated	19	5581	Risk Ratio (M‐H, Random, 95% CI)	1.25 [1.12, 1.39]
2.4 No validation at all	13	7933	Risk Ratio (M‐H, Random, 95% CI)	1.18 [1.08, 1.30]
2.5 > 12 months validation PP outcomes only	1	235	Risk Ratio (M‐H, Random, 95% CI)	1.34 [0.59, 3.01]